Nimotuzumab-induced hypertension: A maiden case report

Ommurugan Balaji, D. Amita Priya, Navin Patil

Research output: Contribution to journalArticlepeer-review


Nimotuzumab is one among the latest humanized monoclonal antibody targeting against epidermal growth factor receptor (EGFR). It is approved for head and neck squamous cancer in India, Srilanka, Cuba and Argentina, for glioma in Cuba, Argentina and Ukraine and nasopharyngeal cancer in China. Hypertension is most common with bevacizumab and cetuximab, which are monoclonal antibodies against EGFR. Hence, we report here a case of nimotuzumab-induced hypertension in a 70-year-old man treated for vocal cord carcinoma.

Original languageEnglish
Pages (from-to)8-9
Number of pages2
JournalAsian Journal of Pharmaceutical and Clinical Research
Issue number4
Publication statusPublished - 01-04-2017

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Pharmaceutical Science
  • Pharmacology (medical)


Dive into the research topics of 'Nimotuzumab-induced hypertension: A maiden case report'. Together they form a unique fingerprint.

Cite this